Does acteoside have effects on colon cancer stem cells via inflamation or apoptosis?

Abstract

Aim: Colon cancer is one of the leading health problems worldwide. Cancer stem cells (CSCs) are referred to as tumor-initiating cells involved in tumor heterogeneity and dormancy. CSCs can cause drug resistance, metastasis, and recurrence of primary and metastatic cancers. Colon cancer stem cells may be an alternative route for effective treatment. In our study, we aimed to evaluate the effects of acteoside on stem cell properties, apoptotic and inflammatory processes in non-metastatic (HCT-116) and metastatic (Colo-741) colon cancer cells and CSCs. Materials and Methods: CSCs were obtained from both types of colon cancer cell lines with the MINIMACS system using the anti-CD133 reagent. After Oct-4 and CD 133 expressions specified, metastatic COLO-741 and non-metastatic HCT-116 CD133+ cancer stem cells and CD133- cancer cells were cultured with or without Acteoside for 48 hours. Immunohistochemical expression of Caspase-3, Bcl-2, Bax, and Fas-L for apoptosis, and IL-1β, TNF-α, IL-6, IL8 and IL-10 proteins for inflammation were statistically analyzed by performing H-Score. Changes in stem cell properties and cell morphology of the cells were determined comparatively before and after the application. Results and Conclusion: Expression of Oct-4 and CD 133 significantly decreased after actoside administration in both metastatic and non-metastatic colon cancer cells. In addition, it was observed that the Bax/Bcl ratio changed in both COLO-741 CD133+ and HTC-116 CD133+ cells. It was determined that acteoside did not affect inflammation in cells immunohistochemically. It has been observed that acteoside can affect the stem cell properties and apoptotic process of colon cancer stem cells.